Regina Fritsche-Danielson
Regina received a PhD in 心血管 Physiology/Pharmacology at the University of 哥德堡 in 1993. 之后，她继续在学术界工作了八年.
During this time she worked at the University of 哥德堡, 渥太华大学, 昆士兰大学和内华达大学. In 1997 she became Associate Professor at the University of 哥德堡.
Regina has a broad scientific background in human and animal physiology, 特别是在心血管生理学方面. She has published over 60 papers and several review articles and book chapters within the field. She has detailed knowledge in the area of regenerative medicine, 动脉粥样硬化, heart failure and cardiovascular physiology – including human disease pathophysiological mechanisms, 医疗需求, current treatment and related pre-clinical science and capabilities.
在澳门在线赌城娱乐的19年里, Regina has held a number of increasingly senior roles spanning from project leader roles for drug projects from early target discovery up to Phase II in clinical development to line management and strategic responsibilities.
2011年1月, Regina was appointed Senior Director and strategy area lead for atherosclerotic cardiovascular disease and she was instrumental in establishing the Cardiac Regeneration research area focusing on heart failure. Regina also led AstraZeneca’s first mRNA programme, VEGF-A from start to Phase II clinical development. In 2014, she was appointed Head of Department Bioscience Heart Failure with overall accountability to initiate and progress the portfolio in the cardiovascular and heart failure area.
In 2017, Regina was appointed Vice President and in 2019 she was promoted to Senior Vice President and Global Head of Early 心血管，肾脏和代谢, 澳门第一赌城在线娱乐R&D with accountabilities from target discovery through clinical proof of concept across small and large molecules leading a group of +340 individuals across all three R&维网站.
最新的项目
高级主管
高级主管
主讲人及小组成员
特色的出版物
Imaging of 动脉粥样硬化 using non-invasive ultrasound
Imaging of Atherosclerosis in WHHL rabbits using non-invasive ultrasound. Wetterholm R, Caidahl K, Volkmann R, Brandt-Eliasson U, Fritsche-Danielson R, Gan LM. 超声医学生物. 2007: 33(5):720-6
动脉粥样硬化的无创实时成像
动脉粥样硬化的无创实时成像 in mice using ultrasound biomicroscopy. 氮化镓,l m.， Grönros, J.， Hägg, U.， Wikström, J. Theodoropoulos, C, Fritsche-Danielson R. 中华动脉粥样硬化杂志，2007,31 (2):313- 319.
Effect of metalloproteinase inhibition on atherosclerotic plaque stability
Effect of broad-spectrum matrix metalloproteinase inhibition on atherosclerotic plaque stability. 约翰逊，j.l.Fritsche-Danielson, R.贝伦特，M. 威斯汀-埃里克森，A.，文波，H.， Herslöf, H.，埃莱布林，M.乔治·S.麦克菲特，W. 杰克逊，c.l. 中华心血管病杂志，2006,31 (3):586-595.
ADAMTS-1在动脉粥样硬化中的作用
ADAMTS-1在动脉粥样硬化中的作用: Remodeling of Carotid Artery, 免疫组织化学, 和蛋白水解. Jönsson-Rylander, A-C, Nilsson T., Fritsche-Danielson R, Hammarstrom一, 贝伦特米, AnderssonJ-O, 林格伦K, Andersson a - k, Wallbrandt P, Brodin P, 席林一, 威斯汀一个, Hurt-Camejo E, Lee-Søgaard碳氢键. 动脉硬化、血栓形成 & 生物工程学报，2009,25(1):391 - 391.
We got some recent data on primary human cardiac progenitor-like cells, where we could actually show that these cells could proliferate and we are now characterizing these cells and studying if they can be differentiated into cardiomyocytes, 内皮细胞和血管平滑肌细胞.
澳门第一赌城在线娱乐的人民 share a common purpose: to push the boundaries of science to deliver life-changing medicines.
故事 from our people and our partners reveal the passion, energy and knowledge that enable us to put science at the heart of everything we do.
澳门第一赌城在线娱乐是全球性的, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide.